DOCSLIB.ORG

Structural and Functional Studies on Myosin Type V

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Structural and Functional Studies on Myosin Type V Dissertation zur Erlangung des Doktorgrades der Fakultät für Chemie und Pharmazie der Ludwig-Maximilians-Universität München Structural and Functional Studies on Myosin Type V Dependent Transport in Vertebrates Hana Velvarská aus Brandeis a.d. Elbe, Tschechische Republik 2012 Erklärung Diese Dissertation wurde im Sinne von § 7 der Promotionsordnung vom 28. November 2011 von Herrn Prof. Dr. Klaus Förstemann betreut. Eidesstattliche Versicherung Diese Dissertation wurde eigenständig, ohne unerlaubte Hilfe erarbeitet. München, ……………………………………… Hana Velvarská Dissertation eingereicht am 24. September 2012 1. Gutachter: Prof. Dr. Klaus Förstemann 2. Gutachter: Prof. Dr. Mario Halic Mündliche Prüfung am 19. November 2012 TABLE OF CONTENTS SUMMARY ................................................................................................................................................. 1 1. INTRODUCTION ............................................................................................................................ 3 1.1 Intracellular transport ............................................................................................................. 3 1.2 Microtubules ................................................................................................................................ 4 1.3 Dynein and kinesin proteins ................................................................................................. 4 1.4 EB1 ................................................................................................................................................... 5 1.5 Actin ................................................................................................................................................. 6 1.6 Unconventional myosins ........................................................................................................ 6 1.7 Type V Myosin ............................................................................................................................. 7 1.8 Type V myosin in human ........................................................................................................ 8 1.8.1 Myo5a ................................................................................................................................................... 9 1.8.2 Myo5b ................................................................................................................................................. 10 1.8.3 Myo5c .................................................................................................................................................. 11 1.8.4 Autoinhibition ................................................................................................................................. 12 1.8.5 Regulation by Ca2+ ......................................................................................................................... 14 1.8.6 Regulation by cargo attachement ........................................................................................... 16 1.8.7 Phosphorylation ............................................................................................................................. 16 1.8.8 Griscelli syndrome ........................................................................................................................ 17 1.9 Melanophilin ............................................................................................................................. 18 1.10 Rab GTPases ............................................................................................................................ 20 1.10.1 Rab27a ............................................................................................................................................. 21 1.10.2 Rab11a ............................................................................................................................................. 22 1.11 Type V myosin in yeast and plants ................................................................................ 22 1.11.1 Myo2p .............................................................................................................................................. 23 1.11.2 Myo4p .............................................................................................................................................. 24 1.11.3 Myosins in plant ........................................................................................................................... 25 1.12 Myo6 ........................................................................................................................................... 25 1.13 Objectives ................................................................................................................................. 27 2. RESULTS ........................................................................................................................................ 28 2.1 Structural studies on Melanophilin ................................................................................. 28 2.1.1 Melanophilin-Rab27a complex ................................................................................................ 28 2.1.2 Melanophilin-Myo5a complex .................................................................................................. 29 2.1.3 Melanophilin-EB1 complex ....................................................................................................... 32 2.2 Structural studies on Myo6 CBD ...................................................................................... 34 2.2.1 Myo6 CBD crystallization ........................................................................................................... 35 2.2.2 Myo6 interaction with Miranda ............................................................................................... 37 2.2.3 Myo6 Initial NMR experiments ................................................................................................ 38 2.3 Structural studies on Myo5a .............................................................................................. 40 2.3.1 Defining the limits of Myo5a GD and crystallization attempts .................................. 40 2.3.2 Shape analysis by Small Angle X-ray Scattering ............................................................... 41 2.3.3 Shape analysis by SAXS of Myo5a, Myo5b, and Myo5c GDs ........................................ 42 2.3.4 Crystallization of the Myo5a GD .............................................................................................. 44 2.3.5 Structure determination of the Myo5a GD ......................................................................... 46 2.3.6 Structure determination of the Myo5b GD ......................................................................... 48 2.3.7 Model of Myo5c GD ....................................................................................................................... 50 2.3.8 Myo5a GD-mutations found to cause Griscelli-syndrome ........................................... 51 2.3.9 Comparison of the human MyoV GD with the yeast type V Myosins ...................... 53 2.3.10 Comparison of surface properties of the Myo5a, Myo5b, and Myo5c GD ........... 54 2.3.11 Investigation of structurally similar proteins ................................................................. 57 2.3.12 Residues required for Myo5a autoinhibition are conserved in Myo5b and Myo5c ...... 58 2.3.13 Not only Myo5a, but also Myo5b and Myo5c GD mediates autoinhibition ........ 59 2.3.14 Binding of Rab11a does not relieve the autoinhibition .............................................. 60 2.3.15 Docking of Myo5a GD crystal structure into EM density of autoinhibited Myo5a ........ 62 2.3.16 The loop I and II of the GD are required for autoinhibition ..................................... 64 2.3.17 A phospho-mimicking mutation in Myo5a loop I abolishes autoinhibition ...... 66 3. DISCUSSION ................................................................................................................................. 67 3.1 Myo5 regulation by autoinhibition ................................................................................. 68 3.2 Myo5 regulation by cargo binding and phosphorylation ...................................... 69 3.3 Regulation by Ca2+ concentration .................................................................................... 71 3.4 The Myo5a autoinhibition model ..................................................................................... 72 4. MATERIALS AND METHODS ................................................................................................ 75 4.1 Chemicals ................................................................................................................................... 75 4.2 DNA Oligonucleotides for cloning .................................................................................... 75 4.3 Plasmids ...................................................................................................................................... 78 4.4 Competent bacterial strains ............................................................................................... 80 4.5 Insect cells lines ....................................................................................................................... 80 4.6 Antibodies .................................................................................................................................
Load more

Recommended publications
  • PSPC1 Potentiates IGF1R Expression to Augment Cell Adhesion and Motility
    1 Supplementary information 2 PSPC1 potentiates IGF1R expression to augment cell 3 adhesion and motility 4 Hsin-Wei Jen1,2 , De-Leung Gu 2, Yaw-Dong Lang 2 and Yuh-Shan Jou 1,2,* 5 1 Graduate Institute of Life Sciences, National Defense Medical Center, Taipei, Taiwan 6 2 Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan 7 * Author to whom correspondence should be addressed 8 Cells 2020, 9, x; doi: FOR PEER REVIEW www.mdpi.com/journal/cells Cells 2020, 9, x FOR PEER REVIEW 2 of 10 9 10 11 Supplementary Figure S1: Expression of IGF1R and integrin in PSPC1-expressing or PSPC1-depleted 12 HCC cells by Western blotting analysis 13 (A) Detection of IGF1R protein levels in three PSPC1-knockdown cells Huh7, HepG2 and Mahlavu. (B) 14 Detection of selected integrin expression in PSPC1-overexpressing or PSPC1-depleted HCC cells by using 15 their total cell lysates immunoblotted with specific integrin antibodies as shown. 16 17 18 Supplementary Figure S2: PSPC1-modulated IGF1R downstream signaling in HCC cells. Cells 2020, 9, x FOR PEER REVIEW 3 of 10 19 (A, B) Immunoblotting of IGF1R expression in PSPC1-overexpressing SK-Hep1 and PLC5 cells 20 treated with IGF1R shRNAs. (C, D) Cell migration and adhesion were measured in PSPC1- 21 knockdown Hep3B cells rescued with exogenous expression of IGF1R. Exogenous expression of 22 IGF1R in PSPC1-knockdown Hep3B cells were then applied for detection of altered AKT/ERK 23 signaling including (E) total PSPC1, IGF1R, AKT, ERK, p-IGF1R, p-AKT(S473), and 24 p-ERK(T202/Y204) as well as altered FAK/Src signaling including (F) total FAK, Src, p-FAK(Y397) 25 and p-Src(Y416) by immunoblotting assay.
    [Show full text]
  • Novel Association of Hypertrophic Cardiomyopathy, Sensorineural Deafness, and a Mutation in Unconventional Myosin VI (MYO6)
    309 LETTER TO JMG J Med Genet: first published as 10.1136/jmg.2003.011973 on 1 April 2004. Downloaded from Novel association of hypertrophic cardiomyopathy, sensorineural deafness, and a mutation in unconventional myosin VI (MYO6) S A Mohiddin, Z M Ahmed, A J Griffith, D Tripodi, T B Friedman, L Fananapazir, R J Morell ............................................................................................................................... J Med Genet 2004;41:309–314. doi: 10.1136/jmg.2003.011973 amilial hypertrophic cardiomyopathy (FHC) is typically Key points characterised by left ventricular hypertrophy, diastolic Fdysfunction, and hypercontractility, and is often asso- ciated with disabling symptoms, arrhythmias, and sudden N Familial hypertrophic cardiomyopathy (FHC) is typi- death.1 FHC shows both non-allelic and allelic genetic cally confined to a cardiac phenotype and is caused by heterogeneity, and results from any one of more than 100 mutations in genes encoding sarcomeric proteins. mutations in genes encoding sarcomeric proteins.2 Identified Occasionally FHC may be one component of a genes include those encoding b myosin heavy chain, the hereditary multisystem disorder. myosin regulatory and essential light chains, myosin bind- N Sensorineural hearing loss is genetically heteroge- ing protein C, troponin I, troponin C, a cardiac actin, and neous. Mutations in the MYO6 gene, encoding 23 titin. The FHC phenotype is characterised by hypertrophy, unconventional myosin VI, have been found to cause myocyte disarray and fibrosis, and results from the dominant non-syndromic sensorineural hearing loss—that is, negative expression of one of these (mainly missense) sensorineural hearing loss in the absence of any other mutations. The resulting sarcomeric dysfunction leads related clinical features. ultimately, through mechanisms that remain obscure, to pathological left ventricular remodelling.
    [Show full text]
  • Notch-Wnt-Bmp Crosstalk Regulates Radial Patterning in the Mouse Cochlea in a Spatiotemporal Manner Vidhya Munnamalai1,2 and Donna M
    © 2016. Published by The Company of Biologists Ltd | Development (2016) 143, 4003-4015 doi:10.1242/dev.139469 RESEARCH ARTICLE Notch-Wnt-Bmp crosstalk regulates radial patterning in the mouse cochlea in a spatiotemporal manner Vidhya Munnamalai1,2 and Donna M. Fekete1,2,3,* ABSTRACT development progresses (Munnamalai and Fekete, 2013). Wnt- The sensory cells of the mammalian organ of Corti assume a precise mediated regulation of cell proliferation is well known in many mosaic arrangement during embryonic development. Manipulation of organ systems, including the cochlea (Jacques et al., 2012). Whether Wnt signaling can modulate the proliferation of cochlear progenitors, the canonical Wnt signaling pathway intersects with the Notch, but whether Wnts are responsible for patterning compartments, or Bmp or Fgf pathways to regulate cochlear patterning remains specific hair cells within them, is unclear. To address how the precise relatively unexplored. timing of Wnt signaling impacts patterning across the radial axis, The Wnt and Notch pathways are known to crosstalk, a finding ‘ ’ mouse cochlear cultures were initiated at embryonic day 12.5 and that coined the term Wntch signaling. This interaction is context subjected to pharmacological treatments at different stages. Early dependent and can be bi-directional (Collu et al., 2014; Zak et al., changes in major patterning genes were assessed to understand the 2015). In the cochlea, Notch has a dual role in regulating lateral mechanisms underlying alterations of compartments. Results show induction early (to induce prosensory fate) and lateral inhibition that Wnt activation can promote medial cell fates by regulating later (to block HC fate) (Kiernan, 2013). Studies have shown that medially expressed Notch genes in a spatiotemporal manner.
    [Show full text]
  • Defining Functional Interactions During Biogenesis of Epithelial Junctions
    ARTICLE Received 11 Dec 2015 | Accepted 13 Oct 2016 | Published 6 Dec 2016 | Updated 5 Jan 2017 DOI: 10.1038/ncomms13542 OPEN Defining functional interactions during biogenesis of epithelial junctions J.C. Erasmus1,*, S. Bruche1,*,w, L. Pizarro1,2,*, N. Maimari1,3,*, T. Poggioli1,w, C. Tomlinson4,J.Lees5, I. Zalivina1,w, A. Wheeler1,w, A. Alberts6, A. Russo2 & V.M.M. Braga1 In spite of extensive recent progress, a comprehensive understanding of how actin cytoskeleton remodelling supports stable junctions remains to be established. Here we design a platform that integrates actin functions with optimized phenotypic clustering and identify new cytoskeletal proteins, their functional hierarchy and pathways that modulate E-cadherin adhesion. Depletion of EEF1A, an actin bundling protein, increases E-cadherin levels at junctions without a corresponding reinforcement of cell–cell contacts. This unexpected result reflects a more dynamic and mobile junctional actin in EEF1A-depleted cells. A partner for EEF1A in cadherin contact maintenance is the formin DIAPH2, which interacts with EEF1A. In contrast, depletion of either the endocytic regulator TRIP10 or the Rho GTPase activator VAV2 reduces E-cadherin levels at junctions. TRIP10 binds to and requires VAV2 function for its junctional localization. Overall, we present new conceptual insights on junction stabilization, which integrate known and novel pathways with impact for epithelial morphogenesis, homeostasis and diseases. 1 National Heart and Lung Institute, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK. 2 Computing Department, Imperial College London, London SW7 2AZ, UK. 3 Bioengineering Department, Faculty of Engineering, Imperial College London, London SW7 2AZ, UK. 4 Department of Surgery & Cancer, Faculty of Medicine, Imperial College London, London SW7 2AZ, UK.
    [Show full text]
  • Conserved Microtubule–Actin Interactions in Cell Movement and Morphogenesis
    REVIEW Conserved microtubule–actin interactions in cell movement and morphogenesis Olga C. Rodriguez, Andrew W. Schaefer, Craig A. Mandato, Paul Forscher, William M. Bement and Clare M. Waterman-Storer Interactions between microtubules and actin are a basic phenomenon that underlies many fundamental processes in which dynamic cellular asymmetries need to be established and maintained. These are processes as diverse as cell motility, neuronal pathfinding, cellular wound healing, cell division and cortical flow. Microtubules and actin exhibit two mechanistic classes of interactions — regulatory and structural. These interactions comprise at least three conserved ‘mechanochemical activity modules’ that perform similar roles in these diverse cell functions. Over the past 35 years, great progress has been made towards under- crosstalk occurs in processes that require dynamic cellular asymme- standing the roles of the microtubule and actin cytoskeletal filament tries to be established or maintained to allow rapid intracellular reor- systems in mechanical cellular processes such as dynamic shape ganization or changes in shape or direction in response to stimuli. change, shape maintenance and intracellular organelle movement. Furthermore, the widespread occurrence of these interactions under- These functions are attributed to the ability of polarized cytoskeletal scores their importance for life, as they occur in diverse cell types polymers to assemble and disassemble rapidly, and to interact with including epithelia, neurons, fibroblasts, oocytes and early embryos, binding proteins and molecular motors that mediate their regulated and across species from yeast to humans. Thus, defining the mecha- movement and/or assembly into higher order structures, such as radial nisms by which actin and microtubules interact is key to understand- arrays or bundles.
    [Show full text]
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus
    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
    [Show full text]
  • Supplemental Tables4.Pdf
    Yano_Supplemental_Table_S4 Gene ontology – Biological process 1 of 9 Fold List Pop Pop GO Term Count % PValue Bonferroni Benjamini FDR Genes Total Hits Total Enrichment DLC1, CADM1, NELL2, CLSTN1, PCDHGA8, CTNNB1, NRCAM, APP, CNTNAP2, FERT2, RAPGEF1, PTPRM, MPDZ, SDK1, PCDH9, PTPRS, VEZT, NRXN1, MYH9, GO:0007155~cell CTNNA2, NCAM1, NCAM2, DDR1, LSAMP, CNTN1, 50 5.61 2.14E-08 510 311 7436 2.34 4.50E-05 4.50E-05 3.70E-05 adhesion ROR2, VCAN, DST, LIMS1, TNC, ASTN1, CTNND2, CTNND1, CDH2, NEO1, CDH4, CD24A, FAT3, PVRL3, TRO, TTYH1, MLLT4, LPP, NLGN1, PCDH19, LAMA1, ITGA9, CDH13, CDON, PSPC1 DLC1, CADM1, NELL2, CLSTN1, PCDHGA8, CTNNB1, NRCAM, APP, CNTNAP2, FERT2, RAPGEF1, PTPRM, MPDZ, SDK1, PCDH9, PTPRS, VEZT, NRXN1, MYH9, GO:0022610~biological CTNNA2, NCAM1, NCAM2, DDR1, LSAMP, CNTN1, 50 5.61 2.14E-08 510 311 7436 2.34 4.50E-05 4.50E-05 3.70E-05 adhesion ROR2, VCAN, DST, LIMS1, TNC, ASTN1, CTNND2, CTNND1, CDH2, NEO1, CDH4, CD24A, FAT3, PVRL3, TRO, TTYH1, MLLT4, LPP, NLGN1, PCDH19, LAMA1, ITGA9, CDH13, CDON, PSPC1 DCC, ENAH, PLXNA2, CAPZA2, ATP5B, ASTN1, PAX6, ZEB2, CDH2, CDH4, GLI3, CD24A, EPHB1, NRCAM, GO:0006928~cell CTTNBP2, EDNRB, APP, PTK2, ETV1, CLASP2, STRBP, 36 4.04 3.46E-07 510 205 7436 2.56 7.28E-04 3.64E-04 5.98E-04 motion NRG1, DCLK1, PLAT, SGPL1, TGFBR1, EVL, MYH9, YWHAE, NCKAP1, CTNNA2, SEMA6A, EPHA4, NDEL1, FYN, LRP6 PLXNA2, ADCY5, PAX6, GLI3, CTNNB1, LPHN2, EDNRB, LPHN3, APP, CSNK2A1, GPR45, NRG1, RAPGEF1, WWOX, SGPL1, TLE4, SPEN, NCAM1, DDR1, GRB10, GRM3, GNAQ, HIPK1, GNB1, HIPK2, PYGO1, GO:0007166~cell RNF138, ROR2, CNTN1,
    [Show full text]
  • Serum Albumin OS=Homo Sapiens
    Protein Name Cluster of Glial fibrillary acidic protein OS=Homo sapiens GN=GFAP PE=1 SV=1 (P14136) Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 Cluster of Isoform 3 of Plectin OS=Homo sapiens GN=PLEC (Q15149-3) Cluster of Hemoglobin subunit beta OS=Homo sapiens GN=HBB PE=1 SV=2 (P68871) Vimentin OS=Homo sapiens GN=VIM PE=1 SV=4 Cluster of Tubulin beta-3 chain OS=Homo sapiens GN=TUBB3 PE=1 SV=2 (Q13509) Cluster of Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 (P60709) Cluster of Tubulin alpha-1B chain OS=Homo sapiens GN=TUBA1B PE=1 SV=1 (P68363) Cluster of Isoform 2 of Spectrin alpha chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTAN1 (Q13813-2) Hemoglobin subunit alpha OS=Homo sapiens GN=HBA1 PE=1 SV=2 Cluster of Spectrin beta chain, non-erythrocytic 1 OS=Homo sapiens GN=SPTBN1 PE=1 SV=2 (Q01082) Cluster of Pyruvate kinase isozymes M1/M2 OS=Homo sapiens GN=PKM PE=1 SV=4 (P14618) Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 Clathrin heavy chain 1 OS=Homo sapiens GN=CLTC PE=1 SV=5 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 Cytoplasmic dynein 1 heavy chain 1 OS=Homo sapiens GN=DYNC1H1 PE=1 SV=5 Cluster of ATPase, Na+/K+ transporting, alpha 2 (+) polypeptide OS=Homo sapiens GN=ATP1A2 PE=3 SV=1 (B1AKY9) Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 Dihydropyrimidinase-related protein 2 OS=Homo sapiens GN=DPYSL2 PE=1 SV=1 Cluster of Alpha-actinin-1 OS=Homo sapiens GN=ACTN1 PE=1 SV=2 (P12814) 60 kDa heat shock protein, mitochondrial OS=Homo
    [Show full text]
  • Myosin Motors: Novel Regulators and Therapeutic Targets in Colorectal Cancer
    cancers Review Myosin Motors: Novel Regulators and Therapeutic Targets in Colorectal Cancer Nayden G. Naydenov 1, Susana Lechuga 1, Emina H. Huang 2 and Andrei I. Ivanov 1,* 1 Department of Inflammation and Immunity, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, OH 44195, USA; [email protected] (N.G.N.); [email protected] (S.L.) 2 Departments of Cancer Biology and Colorectal Surgery, Cleveland Clinic Foundation, Cleveland, OH 44195, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-216-445-5620 Simple Summary: Colorectal cancer (CRC) is a deadly disease that may go undiagnosed until it presents at an advanced metastatic stage for which few interventions are available. The develop- ment and metastatic spread of CRC is driven by remodeling of the actin cytoskeleton in cancer cells. Myosins represent a large family of actin motor proteins that play key roles in regulating actin cytoskeleton architecture and dynamics. Different myosins can move and cross-link actin filaments, attach them to the membrane organelles and translocate vesicles along the actin filaments. These diverse activities determine the key roles of myosins in regulating cell proliferation, differ- entiation and motility. Either mutations or the altered expression of different myosins have been well-documented in CRC; however, the roles of these actin motors in colon cancer development remain poorly understood. The present review aims at summarizing the evidence that implicate myosin motors in regulating CRC growth and metastasis and discusses the mechanisms underlying the oncogenic and tumor-suppressing activities of myosins. Abstract: Colorectal cancer (CRC) remains the third most common cause of cancer and the second most common cause of cancer deaths worldwide.
    [Show full text]
  • Novel Myosin Mutations for Hereditary Hearing Loss Revealed by Targeted Genomic Capture and Massively Parallel Sequencing
    European Journal of Human Genetics (2014) 22, 768–775 & 2014 Macmillan Publishers Limited All rights reserved 1018-4813/14 www.nature.com/ejhg ARTICLE Novel myosin mutations for hereditary hearing loss revealed by targeted genomic capture and massively parallel sequencing Zippora Brownstein1,6, Amal Abu-Rayyan2,6, Daphne Karfunkel-Doron1, Serena Sirigu3, Bella Davidov4, Mordechai Shohat1,4, Moshe Frydman1,5, Anne Houdusse3, Moien Kanaan2 and Karen B Avraham*,1 Hereditary hearing loss is genetically heterogeneous, with a large number of genes and mutations contributing to this sensory, often monogenic, disease. This number, as well as large size, precludes comprehensive genetic diagnosis of all known deafness genes. A combination of targeted genomic capture and massively parallel sequencing (MPS), also referred to as next-generation sequencing, was applied to determine the deafness-causing genes in hearing-impaired individuals from Israeli Jewish and Palestinian Arab families. Among the mutations detected, we identified nine novel mutations in the genes encoding myosin VI, myosin VIIA and myosin XVA, doubling the number of myosin mutations in the Middle East. Myosin VI mutations were identified in this population for the first time. Modeling of the mutations provided predicted mechanisms for the damage they inflict in the molecular motors, leading to impaired function and thus deafness. The myosin mutations span all regions of these molecular motors, leading to a wide range of hearing phenotypes, reinforcing the key role of this family of proteins in auditory function. This study demonstrates that multiple mutations responsible for hearing loss can be identified in a relatively straightforward manner by targeted-gene MPS technology and concludes that this is the optimal genetic diagnostic approach for identification of mutations responsible for hearing loss.
    [Show full text]
  • MYO5A Rabbit Pab
    Leader in Biomolecular Solutions for Life Science MYO5A Rabbit pAb Catalog No.: A9830 Basic Information Background Catalog No. This gene is one of three myosin V heavy-chain genes, belonging to the myosin gene A9830 superfamily. Myosin V is a class of actin-based motor proteins involved in cytoplasmic vesicle transport and anchorage, spindle-pole alignment and mRNA translocation. The Observed MW protein encoded by this gene is abundant in melanocytes and nerve cells. Mutations in 240kDa this gene cause Griscelli syndrome type-1 (GS1), Griscelli syndrome type-3 (GS3) and neuroectodermal melanolysosomal disease, or Elejalde disease. Multiple alternatively Calculated MW spliced transcript variants encoding different isoforms have been reported, but the full- 212kDa/215kDa/218kDa length nature of some variants has not been determined. Category Primary antibody Applications WB,IHC,IF Cross-Reactivity Human, Mouse, Rat Recommended Dilutions Immunogen Information WB 1:500 - 1:2000 Gene ID Swiss Prot 4644 Q9Y4I1 IHC 1:50 - 1:100 Immunogen 1:50 - 1:100 IF Recombinant fusion protein containing a sequence corresponding to amino acids 950-1150 of human MYO5A (NP_000250.3). Synonyms MYO5A;GS1;MYH12;MYO5;MYR12;myosin VA Contact Product Information www.abclonal.com Source Isotype Purification Rabbit IgG Affinity purification Storage Store at -20℃. Avoid freeze / thaw cycles. Buffer: PBS with 0.02% sodium azide,50% glycerol,pH7.3. Validation Data Western blot analysis of extracts of various cell lines, using MYO5A antibody (A9830) at 1:1000 dilution. Secondary antibody: HRP Goat Anti-Rabbit IgG (H+L) (AS014) at 1:10000 dilution. Lysates/proteins: 25ug per lane. Blocking buffer: 3% nonfat dry milk in TBST.
    [Show full text]
  • Genome-Wide Identification, Characterization and Expression
    G C A T T A C G G C A T genes Article Genome-Wide Identification, Characterization and Expression Profiling of myosin Family Genes in Sebastes schlegelii Chaofan Jin 1, Mengya Wang 1,2, Weihao Song 1 , Xiangfu Kong 1, Fengyan Zhang 1, Quanqi Zhang 1,2,3 and Yan He 1,2,* 1 MOE Key Laboratory of Molecular Genetics and Breeding, College of Marine Life Sciences, Ocean University of China, Qingdao 266003, China; [email protected] (C.J.); [email protected] (M.W.); [email protected] (W.S.); [email protected] (X.K.); [email protected] (F.Z.); [email protected] (Q.Z.) 2 Laboratory of Tropical Marine Germplasm Resources and Breeding Engineering, Sanya Oceanographic Institution, Ocean University of China, Sanya 572000, China 3 Laboratory for Marine Fisheries Science and Food Production Processes, Qingdao National Laboratory for Marine Science and Technology, Qingdao 266003, China * Correspondence: [email protected]; Tel.: +86-0532-82031986 Abstract: Myosins are important eukaryotic motor proteins that bind actin and utilize the energy of ATP hydrolysis to perform a broad range of functions such as muscle contraction, cell migration, cytokinesis, and intracellular trafficking. However, the characterization and function of myosin is poorly studied in teleost fish. In this study, we identified 60 myosin family genes in a marine teleost, black rockfish (Sebastes schlegelii), and further characterized their expression patterns. myosin showed divergent expression patterns in adult tissues, indicating they are involved in different types and Citation: Jin, C.; Wang, M.; Song, W.; compositions of muscle fibers. Among 12 subfamilies, S. schlegelii myo2 subfamily was significantly Kong, X.; Zhang, F.; Zhang, Q.; He, Y.
    [Show full text]